Risk factors associated with cytomegalovirus reactivation in patients receiving immunosuppressive therapy for rheumatic diseases: a retrospective study.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
03 12 2022
03 12 2022
Historique:
received:
26
07
2022
accepted:
30
11
2022
entrez:
3
12
2022
pubmed:
4
12
2022
medline:
7
12
2022
Statut:
epublish
Résumé
Immunosuppressive treatment is a common cause of cytomegalovirus (CMV) reactivation. However, there is no consensus regarding the risk factors for CMV reactivation in rheumatic diseases. Therefore, this study aimed to elucidate the risk factors associated with CMV reactivation. We retrospectively collected the data of 472 patients with rheumatic diseases whose CMV pp65 antigen (C7-HRP) titer was measured. We divided the patients into those with and those without C7-HRP. We retrospectively collected data on age, sex, primary condition and organ involvement, and blood test results. We also investigated the use of immunosuppressants and the maximum and cumulative doses of prednisolone (PSL). We performed univariate and multivariate analyses to identify risk factors for CMV reactivation. Multivariate analysis showed that higher age (71.2 vs. 64.4 years, p = 0.0022), hypoalbuminemia (2.9 vs. 3.4 g/dL, p = 0.0104), higher creatinine level (1.2 vs. 0.9 mg/dL, p = 0.0026), cyclosporine use (8.2 vs. 3.6%, p = 0.0101), and higher maximum (552.4 vs. 243.3 mg, p < 0.0001) and cumulative (2785.9 vs. 1330.5 mg, p < 0.0001) doses of PSL were associated with CMV reactivation. Older age, hypoalbuminemia, higher creatinine level, cyclosporine use, and higher maximum and cumulative doses of PSL were significant risk factors for CMV reactivation in rheumatic diseases.
Identifiants
pubmed: 36463264
doi: 10.1038/s41598-022-25451-4
pii: 10.1038/s41598-022-25451-4
pmc: PMC9719476
doi:
Substances chimiques
Creatinine
AYI8EX34EU
Prednisolone
9PHQ9Y1OLM
Immunosuppressive Agents
0
Cyclosporins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20926Informations de copyright
© 2022. The Author(s).
Références
Takizawa, Y. et al. Clinical characteristics of cytomegalovirus infection in rheumatic diseases: Multicentre survey in a large patient population. Rheumatology (Oxford) 47, 1373–1378 (2008).
doi: 10.1093/rheumatology/ken231
pubmed: 18577548
Kaneshita, S. et al. Risk factors for cytomegalovirus disease with cytomegalovirus re-activation in patients with rheumatic disease. Mod. Rheumatol. 30, 109–115 (2020).
doi: 10.1080/14397595.2018.1551264
pubmed: 30472908
Choo, H. M. C., Cher, W. Q., Kwan, Yu. H. & Fong, W. W. S. Risk factors for cytomegalovirus disease in systemic lupus erythematosus (SLE): A systematic review. Adv. Rheumatol. 59, 12 (2019).
doi: 10.1186/s42358-019-0055-y
pubmed: 30885265
Hanaoka, R. et al. Reactivation of cytomegalovirus predicts poor prognosis in patients on intensive immunosuppressive treatment for collagen-vascular diseases. Mod. Rheumatol. 22, 438–445 (2012).
doi: 10.3109/s10165-011-0519-3
pubmed: 21915676
Fujimoto, D., Matsushima, A., Nagao, M., Takakura, S. & Ichiyama, S. Risk factors associated with elevated blood cytomegalovirus pp65 antigen levels in patients with autoimmune diseases. Mod. Rheumatol. 23, 345–350 (2013).
doi: 10.3109/s10165-012-0651-8
pubmed: 22534885
Pawelec, G., McElhaney, J. E., Aiello, A. E. & Derhovanessian, E. The impact of CMV infection on survival in older humans. Curr. Opin. Immunol. 24, 507–511 (2012).
doi: 10.1016/j.coi.2012.04.002
pubmed: 22541724
Khan, N. et al. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J. Immunol. 169, 1984–1992 (2002).
doi: 10.4049/jimmunol.169.4.1984
pubmed: 12165524
Lim, E. Y., Jackson, S. E. & Wills, M. R. The CD4+ T cell response to human cytomegalovirus in healthy and immunocompromised people. Front. Cell. Infect. Microbiol. 10, 202 (2020).
doi: 10.3389/fcimb.2020.00202
pubmed: 32509591
pmcid: 7248300
Hadrup, S. R. et al. Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly. J. Immunol. 176, 2645–2653 (2006).
doi: 10.4049/jimmunol.176.4.2645
pubmed: 16456027
Gardiner, B. J., Haas, E. M., Bailey, R. C., Chow, J. K. & Snydman, D. R. Reactivation of latent cytomegalovirus infection in patients with rheumatologic disease: A case-control study. Rheumatol. Int. 39, 1229–1240 (2019).
doi: 10.1007/s00296-019-04324-6
pubmed: 31076831
Wanchu, A., Suryanaryana, B. S., Sharma, S., Sharma, A. & Bambery, P. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: A prospective open study. Int. J. Rheum. Dis. 12, 239–242 (2009).
doi: 10.1111/j.1756-185X.2009.01417.x
pubmed: 20374353
Bolton, W. K. & Sturgill, B. C. Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis. Am. J. Nephrol. 9, 368–375 (1989).
doi: 10.1159/000167998
pubmed: 2801784
Nachman, P. H., Hogan, S. L., Jennette, J. C. & Falk, R. J. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J. Am. Soc. Nephrol. 7, 33–39 (1996).
doi: 10.1681/ASN.V7133
pubmed: 8808107
Adu, D. et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. Q. J. Med. 90, 401–409 (1997).
doi: 10.1093/qjmed/90.6.401
Hogan, S. L. et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann. Intern. Med. 143, 621–631 (2005).
doi: 10.7326/0003-4819-143-9-200511010-00005
pubmed: 16263884
Takakuwa, Y. et al. Low-dose rituximab as induction therapy for ANCA-associated vasculitis. Clin. Rheumatol. 38, 1217–1223 (2019).
doi: 10.1007/s10067-019-04443-2
pubmed: 30680533
Ayan, G. et al. Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: Experience of a single center and systematic review of non-randomized studies. Rheumatol. Int. 38, 607–622 (2018).
doi: 10.1007/s00296-018-3928-1
pubmed: 29322343
Fauci, A. S. & Dale, D. C. The effect of in vivo hydrocortisone on subpopulations of human lymphocytes. J. Clin. Investig. 53, 240–246 (1974).
doi: 10.1172/JCI107544
pubmed: 4808638
pmcid: 301459
Yao, Z., DuBois, D. C., Almon, R. R. & Jusko, W. J. Pharmacokinetic/pharmacodynamic modeling of corticosterone suppression and lymphocytopenia by methylprednisolone in rats. J. Pharm. Sci. 97, 2820–2832 (2008).
doi: 10.1002/jps.21167
pubmed: 17828751
pmcid: 3726057
Bromberg, L. et al. Methylprednisolone-induced lymphocytosis in patients with immune-mediated inflammatory disorders. Am. J. Med. 129, 746-752.e3 (2016).
doi: 10.1016/j.amjmed.2016.02.013
pubmed: 26968468
Ota, Y., Kaneko, Y. & Takeuchi, T. Association between mortality and cytomegalovirus reactivation during remission induction therapy in patients with rheumatic diseases. Clin. Exp. Rheumatol. 39, 1324–1330 (2021).
doi: 10.55563/clinexprheumatol/pqa98i
pubmed: 33338008
Morishita, M. et al. Risk factors for cytomegalovirus infection in patients with antineutrophil cytoplasmic antibody-associated vasculitis. PLoS ONE 14, e0218705 (2019).
doi: 10.1371/journal.pone.0218705
pubmed: 31291263
pmcid: 6619987
Hughes, E. et al. T-cell modulation by cyclophosphamide for tumour therapy. Immunology 154, 62–68 (2018).
doi: 10.1111/imm.12913
pubmed: 29460448
pmcid: 5904691
Bensalem, A. et al. CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritis. Br. J. Clin. Pharmacol. 85, 2747–2758 (2019).
doi: 10.1111/bcp.14102
pubmed: 31454097
pmcid: 6955400
Liossis, S. N. & Sfikakis, P. P. Rituximab-induced B cell depletion in autoimmune diseases: Potential effects on T cells. Clin. Immunol. 127, 280–285 (2008).
doi: 10.1016/j.clim.2008.01.011
pubmed: 18337174
Rudulier, C. D., Kroeger, D. R. & Bretscher, P. A. Distinct roles of dendritic and B cells in the activation of naive CD4+ T cells. Immunotherapy 4, 355–357 (2012).
doi: 10.2217/imt.12.17
pubmed: 22512626
Takemura, S., Klimiuk, P. A., Braun, A., Goronzy, J. J. & Weyand, C. M. T cell activation in rheumatoid synovium is B cell dependent. J. Immunol. 167, 4710–4718 (2001).
doi: 10.4049/jimmunol.167.8.4710
pubmed: 11591802
Huss, R., Hoy, C. A., Ottinger, H., Grosse-Wilde, H. & Deeg, H. J. Cyclosporine-induced apoptosis in CD4+ T lymphocytes and computer-simulated analysis: Modeling a treatment scenario for HIV infection. Res. Immunol. 146, 101–108 (1995).
doi: 10.1016/0923-2494(96)80243-4
pubmed: 7481073
Matsuda, S. & Koyasu, S. Mechanisms of action of cyclosporine. Immunopharmacology 47, 119–125 (2000).
doi: 10.1016/S0162-3109(00)00192-2
pubmed: 10878286
Gandhi, M. K. & Khanna, R. Human cytomegalovirus: Clinical aspects, immune regulation, and emerging treatments. Lancet Infect. Dis. 4, 725–738 (2004).
doi: 10.1016/S1473-3099(04)01202-2
pubmed: 15567122
Steininger, C. Clinical relevance of cytomegalovirus infection in patients with disorders of the immune system. Clin. Microbiol. Infect. 13, 953–963 (2007).
doi: 10.1111/j.1469-0691.2007.01781.x
pubmed: 17803749
Sissons, J. G. P. & Carmichael, A. J. Clinical aspects and management of cytomegalovirus infection. J. Infect. 44, 78–83 (2002).
doi: 10.1053/jinf.2001.0949
pubmed: 12076065
Almeida-Porada, G. D. & Ascensăo, J. L. Cytomegalovirus as a cause of pancytopenia. Leuk. Lymphoma 21, 217–223 (1996).
doi: 10.3109/10428199209067603
pubmed: 8726402
Shragai, T. et al. Characteristics and outcomes of adults with cytomegalovirus-associated thrombocytopenia: A case series and literature review. Br. J. Haematol. 191, 863–867 (2020).
doi: 10.1111/bjh.17017
pubmed: 32744725
Nomura, K. et al. Thrombocytopenia due to cytomegalovirus infection in an immunocompetent adult. Hematology 10, 405–406 (2005).
doi: 10.1080/10245330500141556
pubmed: 16273730
Takizawa, Y. et al. Clinical characteristics of cytomegalovirus infection in rheumatic diseases: Multicentre survey in a large patient population. Rheumatol. (Oxf. Engl.) 47, 1373–1378 (2008).
doi: 10.1093/rheumatology/ken231